DUBLIN, October 3, 2017 /PRNewswire/ --
The "Global Diabetic Retinopathy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025" report has been added to Research and Markets' offering.
The global diabetic retinopathy market was valued at USD 8.4 Bn in 2017, and is expected to reach USD 13.1 Bn by 2025, expanding at a CAGR of 6.7% from 2017 - 2025.
Perpetual growth in the prevalence of diabetes in middle- and low-income countries and further anticipation of future rise indicates the growth in prevalence of diabetic related complications, and hence diabetic retinopathy. Diabetic retinopathy is among the key causes of legal blindness in working adult population. With overall prevalence of around 34% in the total diabetes population, the burden in form of direct and indirect management cost of diabetic retinopathy is humongous. Treatment for diabetic retinopathy is determined upon the severity of condition, where non-proliferative diabetic retinopathy is excuses from treatment.
Along with high prevalence of diabetes and hence diabetic retinopathy, wide availability of treatment options also serve as key drivers of this market. At present, diabetic retinopathy is mostly treated with laser treatment and vitrectomy. As the prevalence of macular edema in diabetic retinopathy is on rise, it is anticipated that the demand for treatment drugs and injections will steadily grow. Rise in healthcare expenditure is another key contributor to the growth of diabetic retinopathy market.
However, the market growth may be shunted due to shortage of skilled professional for treating diabetes and related complications. The key diabetic retinopathy treatment drugs studied in this report are Aflibercept (Eylea), Bevacizumab (Avastin), Fluocinolone acetonide (Iluvien), Ranibizumab (Lucentis) and Triamcinolone acetonide.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
2.1 Diabetic Retinopathy Treatment Devices Market, by Type, 2015 (USD Mn)
2.2 Diabetic Retinopathy Treatment Drugs Market, by Type, 2015 (USD Mn)
2.3 Diabetic Retinopathy Market Share, by Geography, 2015 (Value %)
Chapter 3 Diabetic Retinopathy Market: Market Dynamics and Outlook
3.2 Diabetic Retinopathy: Facts and Figures
3.5 Future Prospects
3.6 Attractive Investment Proposition
3.1 Competitive Analysis: Market Positioning, by Key Market Players
Chapter 4 Global Diabetic Retinopathy Treatment Devices Market Analysis, by Device Type, 2015 - 2025 (USD Mn)
4.2 Focal Laser Treatment
4.3 Scatter Laser Treatment
4.4 Vitrectomy Devices
Chapter 5 Global Diabetic Retinopathy Drugs Market Analysis, by Drug Type, 2015 - 2025 (USD Mn)
5.2 Aflibercept (Eylea)
5.3 Bevacizumab (Avastin)
5.4 Fluocinolone Acetonide (Iluvien)
5.5 Ranibizumab (Lucentis)
5.6 Triamcinolone Acetonide Injection
Chapter 6 Global Diabetic Retinopathy Market, by Geography, 2015 - 2025 (USD Mn)
Chapter 7 Company Profiles
- Alimera Sciences, Inc
- Genentech USA, Inc.
- Sandoz Inc.
- Bayer Pharma AG
- Regeneron Pharmaceuticals Inc.
- Iridex Corporation
- Valon Lasers OY
- Other Notable Players
For more information about this report visit https://www.researchandmarkets.com/research/jcqml4/global_diabetic
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets